Rebut-Bonneton C, Demignon J, Cancela L, Miravet L
Reprod Nutr Dev (1980). 1985;25(3):583-90. doi: 10.1051/rnd:19850410.
Two groups of female rats were used to investigate vitamin D metabolism in the pregnant animals and in their fetuses. In the first group, 3 micrograms of 25-hydroxyvitamin D3 (25-OH-D3) per kg of body weight were injected into intact or nephrectomized (NX) pregnant rats 3 h before sacrifice on day 21 of pregnancy; in the second group, 2 and 6 ng, respectively, of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) per day were infused continuously into pregnant rats between days 17 and 21 of pregnancy. The findings in the fetuses were obtained by quantitative analysis of extracts (Extrelut) of total fetal body lipids; the extracts were purified on Sep Pak and vitamin D sterols were further separated by high-pressure liquid chromatography. Three hours after the dams were injected with 25-OH-D3, the maternal plasma concentration (mean +/- SD) of 1,25(OH)2D3 was 221 +/- 84 pg/ml. In NX pregnant rats, the 1,25(OH)2D3 levels were still elevated: 95.6 +/- 49.0 pg/ml vs 45 +/- 22 pg/ml in control rats. In fetuses from intact or NX dams, the levels of 25-OH-D3 and 1,25(OH)2D3 were not different from the results obtained in the control fetuses but 24,25(OH)2D3 concentrations were increased (6.7 +/- 1.2 ng vs 2.2 +/- 0.7 ng/g body weight). After maternal infusion of 2 or 6 ng/day of 1,25(OH)2D3 (n = 8), plasma concentrations (mean +/- SD) of the metabolite were 64 +/- 31 and 517 +/- 356 pg/ml, respectively, the second being significantly higher than that of the control rats; 25-OH-D3 and 24,25(OH)2D3 levels did not change. 1,25(OH)2D3 contents (mean +/- SD) in fetuses from the treated dams were not different from those of control fetuses (10 +/- 2 pg/g body weight). Our results suggest that pregnant rats and their fetuses were protected against an excessive increase of 1,25(OH)2D3 concentrations in the maternal plasma; although there was some individual hypercalcemia, no significant increase in mean calcemia was detected in the dams, and 1,25(OH)2D3 either did not cross the placental barrier or was rapidly metabolized because we did not find any changes in the fetal content. As in intact or NX pregnant rats, 25-OH-D3 was metabolized into 1,25(OH)2D3, the increase of 24,25(OH)2D3 in the fetuses might be associated with a protective mechanism.
两组雌性大鼠被用于研究怀孕动物及其胎儿体内的维生素D代谢情况。第一组,在怀孕第21天处死前3小时,给完整或肾切除(NX)的怀孕大鼠每千克体重注射3微克的25-羟基维生素D3(25-OH-D3);第二组,在怀孕第17天至21天期间,每天分别给怀孕大鼠持续输注2纳克和6纳克的1,25-二羟基维生素D3(1,25(OH)2D3)。通过对整个胎儿身体脂质提取物(Extrelut)进行定量分析来获取胎儿的研究结果;提取物在Sep Pak上进行纯化,维生素D甾醇通过高压液相色谱进一步分离。母鼠注射25-OH-D3三小时后,母体血浆中1,25(OH)2D3的浓度(平均值±标准差)为221±84皮克/毫升。在NX怀孕大鼠中,1,25(OH)2D3水平仍然升高:与对照大鼠的45±22皮克/毫升相比为95.6±49.0皮克/毫升。在完整或NX母鼠的胎儿中,25-OH-D3和1,25(OH)2D3的水平与对照胎儿的结果没有差异,但24,25(OH)2D3的浓度增加了(6.7±1.2纳克/克体重,对照为2.2±0.7纳克/克体重)。在母鼠每天输注2纳克或6纳克1,25(OH)2D3(n = 8)后,该代谢物的血浆浓度(平均值±标准差)分别为64±31和517±356皮克/毫升,后者显著高于对照大鼠;25-OH-D3和24,25(OH)2D3水平没有变化。经处理的母鼠所产胎儿中1,25(OH)2D3的含量(平均值±标准差)与对照胎儿没有差异(10±2皮克/克体重)。我们的结果表明,怀孕大鼠及其胎儿可免受母体血浆中1,25(OH)2D3浓度过度升高的影响;尽管有一些个体出现高钙血症,但在母鼠中未检测到平均血钙有显著增加,并且1,25(OH)2D3要么没有穿过胎盘屏障,要么被迅速代谢,因为我们在胎儿含量中未发现任何变化。与完整或NX怀孕大鼠一样,25-OH-D3被代谢为1,25(OH)2D3,胎儿中24,25(OH)2D3的增加可能与一种保护机制有关。